AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC
AdvanTIG-204：一项 II 期随机、开放标签研究，比较 Ociperlimab 联合 Tislelizumab 和同步放化疗与 Tislelizumab 联合同步化疗以及同步放化疗在局限期小细胞肺癌一线治疗中的疗效。
期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100911
Gong, Youling; Pang, Qingsong; Yu, Rong; Zhu, Zhengfei; Huang, Jiangqiong; Cheng, Yufeng; Zhong, Diansheng; Wu, Hongbo; Yoo, Seung Soo; Dobbs, Tracy; Bao, Zinan; Zuo, Yunxia; Gao, Yujuan; Sun, Pu; Lu, You
